CTIS2023-508474-29-00进行中（未招募）1 期
ong-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis. - 220723
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 158
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participants with a diagnosis of moderate to severe AtD who have completed the qualifying Ph2 parent GSK AtD studies, who, in the opinion of the investigator, may benefit from treatment with GSK1070806. Participant must be 18 years of age inclusive, or older at the time of signing the informed consent. Participant must sign and date an informed consent. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
排除标准
- •Had study intervention permanently discontinued at any time during a qualifying Ph2 parent GSK AtD clinical study, or developed a medical condition that would preclude participation as per qualifying Ph2 parent GSK AtD clinical study protocol. Participants who, during their participation in qualifying Ph2 parent GSK AtD clinical study, developed an AE or an SAE based on laboratory parameters, physical examination, vital signs, ECG, medical history, which in the opinion of the Investigator could indicate that continued treatment with IMP may present an unreasonable risk for the participant.
研究者
相似试验
进行中（未招募）
1 期
Extension study to evaluate the long-term outcomes of subjects in study 20090MedDRA version: 20.1Level: PTClassification code: 10038933Term: Retinopathy of prematurity Class: 100000004853Retinopathy of prematurityCTIS2023-504207-89-00Bayer AG97
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.EUCTR2021-002344-73-DESanofi-aventis recherche & développement315
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.EUCTR2021-002344-73-HUSanofi-aventis recherche & développement315
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.Dermatitis atopicMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-002344-73-CZSanofi-aventis recherche & développement315
招募中
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitisCTIS2023-506548-18-00Sanofi-Aventis Research & Development306